Summit Therapeutics Inc. Common Stock (SMMT)

Price$14.77

Value ScoreF

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-25.37%

Price vs S&P 500 (4W)-18.30%

VGM Score23.58

Market Capitalization$11.46B

All Metrics

Book Value / Share (Quarterly)$0.70

P/TBV (Annual)6.75x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.50

Price vs S&P 500 (YTD)-23.71%

Net Profit Margin (TTM)-9027.08%

EPS (TTM)$-1.60

10-Day Avg Trading Volume7.19M

EPS Excl Extra (TTM)$-1.60

EPS (Annual)$-0.31

ROI (Annual)-56.93%

Net Profit Margin (5Y Avg)-5207.57%

Cash / Share (Quarterly)$0.77

ROA (Last FY)-50.81%

EBITD / Share (TTM)$-1.61

ROE (5Y Avg)-216.65%

Operating Margin (TTM)-8108.33%

Cash Flow / Share (Annual)$-0.42

P/B Ratio21.00x

P/B Ratio (Quarterly)26.93x

Net Income / Employee (Annual)$-835,200

EV / Revenue (TTM)11830.63x

Net Interest Coverage (TTM)-121.35x

ROA (TTM)-243.07%

EPS Incl Extra (Annual)$-0.31

Current Ratio (Annual)9.87x

Quick Ratio (Quarterly)7.19x

3-Month Avg Trading Volume3.70M

52-Week Price Return-25.14%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.60

P/S Ratio (Annual)16146.37x

Asset Turnover (Annual)0.00x

52-Week High$30.98

Operating Margin (5Y Avg)-4960.39%

EPS Excl Extra (Annual)$-0.31

CapEx CAGR (5Y)9.36%

26-Week Price Return-17.44%

Quick Ratio (Annual)9.78x

13-Week Price Return-1.14%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)7.41x

Enterprise Value$11.36B

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-2.46%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-11095.77%

Cash / Share (Annual)$0.92

3-Month Return Std Dev92.17%

Net Income / Employee (TTM)$-4,551,300

ROE (Last FY)-56.93%

Net Interest Coverage (Annual)-67.22x

EPS Basic Excl Extra (Annual)$-0.31

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.60

Receivables Turnover (Annual)0.00x

ROI (TTM)-291.24%

P/S Ratio (TTM)11941.59x

Pretax Margin (5Y Avg)-5211.66%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.60

Price vs S&P 500 (52W)-49.51%

Year-to-Date Return-15.55%

5-Day Price Return-5.98%

EPS Normalized (Annual)$-0.31

ROA (5Y Avg)-99.04%

Net Profit Margin (Annual)-11095.77%

Month-to-Date Return-15.79%

Cash Flow / Share (TTM)$-1.21

EBITD / Share (Annual)$-0.31

Operating Margin (Annual)-10153.52%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-117.59%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.60

P/TBV (Quarterly)6.75x

P/B Ratio (Annual)19.76x

Pretax Margin (TTM)-9027.08%

Book Value / Share (Annual)$0.85

Price vs S&P 500 (13W)-9.39%

Beta-1.33x

Revenue / Share (TTM)$0.00

ROE (TTM)-291.24%

52-Week Low$13.83

vGradeF

mGradeC

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.24est. -0.18

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.96

3.87

3.92

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	$14.77
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Summit Therapeutics is a biopharmaceutical company focused on developing novel antibiotics for serious infectious diseases. Its lead product candidate, ridinilazole, is an orally administered antibiotic designed to treat Clostridioides difficile infections (CDI). The company operates in the United States and United Kingdom.